Clinical Trials Logo

Filter by:
NCT ID: NCT04024345 Active, not recruiting - Pancreatic Cancer Clinical Trials

The Emotional Impact of Surveillance for Pancreatic Cancer

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Due to its rarity a population screening program for pancreatic cancer is not possible. For this reason, considering background data on genetic predisposition and familiarity for this lethal tumor, efforts have been pushed to build up surveillance programs for subjects at high-risk of pancreatic cancer, due to familiarity and/or genetic predisposition. These programs are based on radiological examinations (such as MRI or endoultrasonography) and laboratory tests. However, little is known about the psychological burden of these programs. Only a handful of studies investigated, in various ways, how the participation in surveillance programs for pancreatic cancer may burden the psychological status, with a consequent possible impairment of the psychological wellbeing, and a higher risk of withdraw from the surveillance program itself. The aim of this study was to assess the psychological and emotional impact in high-risk individuals participating in a surveillance program for pancreatic cancer due to familiarity and/or to genetic predisposition, using specific psychological tools, such as multiple psychological questionnaires, investigating different functioning areas, administered by a clinical psychologist.

NCT ID: NCT04023552 Active, not recruiting - Clinical trials for Cardiovascular Disease and Lipoprotein(a)

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Lp(a)HORIZON
Start date: December 12, 2019
Phase: Phase 3
Study type: Interventional

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

NCT ID: NCT04023526 Active, not recruiting - Clinical trials for Leukemia, Myeloid, Acute

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

CULMINATE
Start date: July 29, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.

NCT ID: NCT04023396 Active, not recruiting - Ulcerative Colitis Clinical Trials

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

Start date: January 13, 2020
Phase: Phase 2
Study type: Interventional

A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.

NCT ID: NCT04020354 Active, not recruiting - Cerebral Palsy Clinical Trials

Changes Induced by Early HABIT-ILE in Pre-school Children With Uni- and Bilateral Cerebral Palsy

EarlyHABIT-ILE
Start date: November 27, 2018
Phase: N/A
Study type: Interventional

Studying in two randomized controlled trials (RCT) the changes induced by early HABIT-ILE in functional, neuroplastic and biomechanical assessment in children with unilateral and bilateral CP.

NCT ID: NCT04015180 Active, not recruiting - Clinical trials for Retinopathy of Prematurity (ROP)

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

FIREFLEYE next
Start date: March 18, 2020
Phase: Phase 3
Study type: Interventional

This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.

NCT ID: NCT04011722 Active, not recruiting - Clinical trials for Symptomatic Severe Aortic Stenosis

Portico NG Approval Study

Start date: September 17, 2019
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Porticoâ„¢ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

NCT ID: NCT04009499 Active, not recruiting - Psoriatic Arthritis Clinical Trials

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

BE VITAL
Start date: August 13, 2019
Phase: Phase 3
Study type: Interventional

This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).

NCT ID: NCT04009291 Active, not recruiting - Clinical trials for Endocrine System Diseases

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

PaTH Forward
Start date: August 27, 2019
Phase: Phase 2
Study type: Interventional

During the first four weeks of the trial, participants will be randomly assigned to one of four groups: three groups will receive fixed doses of TransCon PTH and one group will receive placebo. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the four weeks, participants will continue in the trial as part of a long-term extension study. During the extension, all participants will receive TransCon PTH, with the dose adjusted to their individual needs. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Germany, Denmark, and Norway.

NCT ID: NCT04009161 Active, not recruiting - Clinical trials for Head and Neck Cancer

Osteoradionecrosis Rate in Patients Undergoing Radiotherapy for Head and Neck Cancer Treatment.

Start date: March 14, 2017
Phase:
Study type: Observational

Objectives High-dose radiotherapy (RT) for head and neck cancer has significant adverse effects on maxillofacial tissues, among which osteoradionecrosis (ORN) is the most severe and potentially life-threatening. Although tooth extractions seem to be the main risk factor, few perspective studies evaluated protocols to minimize the ORN risk due to extractions. The aim of this study is to evaluate incidence and risk factors of ORN in a cohort of patients receiving tooth extractions before RT and evaluate an algorithm about extraction decision. Methods One-hundred ten patients were consecutively recruited in this study: impacted third molars with radiographic sign of pericoronitis, teeth with periapical lesions, unrestorable teeth, periodontally compromised teeth (pocket probing depth >5 mm, clinical attachment loss > 8 mm, grade 2 tooth mobility, II grade furcation involvement) were extracted under antibiotic prophylaxis. A 15-days interval between the last tooth extraction and the beginning of RT was recommended. Patients were visited at 15 days, 1, 3 and 6 months after the beginning of RT. Data of patients with a minimum of 6 months follow-up are presented in this report. ORN was defined as irradiated exposed necrotic bone, without healing for 3 months, in absence of cancer recurrence. The protocol was approved by the Ethic Committee of Catholic University - Fondazione Policlinico Gemelli (Prot. OHHN-1, ID-2132).